PBI scientists will discuss latest developments in biomarkers for metabolic syndrome. Topics: 1) Pre-analytical and analytical concerns regarding gut and incretin hormones, 2) Dysfunctional HDL biomarkers in metabolic syndrome, and 3) Kidney Injury Markers and their usefulness in diabetic nephropathy. Attendees would include scientists and physicians involved in drug-development with focus on biomarker selections for clinical trials.
